Author

C. E. Barbieri

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Organism:mouse· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

B. D. Robinson· 2 shared F. Khani· 2 shared A. Sboner· 1 shared C. Abate-Shen· 1 shared C. D. Gaffney· 1 shared C. Fidalgo-Ribeiro· 1 shared C. Unkenholz· 1 shared D. Huang· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. D. Robinson

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Distinct mesenchymal cell states mediate prostate cancer progression

H. Pakula, M. Omar, R. Carelli, F. Pederzoli, G. N. Fanelli, T. Pannellini, L. Van Emmenis, S. Rodrigues, C. Fidalgo-Ribeiro, P. V. Nuzzo, N. J. Brady, M. Jere, C. Unkenholz, M. K. Alexanderani, F. Khani, , M. Loda

This study identifies distinct mesenchymal cell states in prostate cancer stroma that correlate with metastatic progression and develops a gene signature to predict patient outcomes.

bioRxiv · Mar 29, 2023Cancer Biology

SPOP mutation confers sensitivity to AR-targeted therapy in prostate cancer by reshaping the androgen-driven chromatin landscape

I. Grbesa, M. A. Augello, D. Liu, D. R. McNally, C. D. Gaffney, D. Huang, K. Lin, R. Goueli, B. D. Robinson, F. Khani, L. D. Deonarine, M. Blattner, O. Elemento, E. Davicioni, A. Sboner, C. E. Barbieri

This study shows that SPOP mutations in prostate cancer alter the chromatin landscape and AR-driven transcription, making tumors more responsive to AR-targeted therapies.

bioRxiv · Apr 20, 2021 · PreprintCancer Biology